Reports
Reports
The global haemorrhagic stroke treatment market is expected to grow at a CAGR of 4.10% during the period 2023-2028. While rates of incidence of haemorrhagic stroke are heterogenous across the globe, Low and Middle Income countries (LMIC) such as those in Asia and Africa have been witnessing an upward trend.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
While there is significant regional difference in incidence rates of haemorrhagic stroke, highest rates have been observed in LMIC regions such as sub-Saharan Africa and East Asia.
It is estimated that nearly 750,000 strokes take place in the USA every year. During a stroke, one or more regions in the brain may suffer damage, and an individual may experience loss of ability to move to one side of the body depending on the region affected. The damage may be permanent or temporary, and loss of function may be partial or full. Long-term outcome depends on the extent of brain damage, how quickly treatment starts, and several other factors.
Strokes may lead to long-lasting injury, disability, and even death. Early treatment and precautionary measures may decrease brain damage due to stroke. Treatment depends on stroke type (e.g. ischemic or haemorrhagic), the time since the first stroke symptoms appeared, and the individual’s underlying medical issues. Haemorrhage refers to bleeding. Haemorrhagic stroke takes place when blood vessels in the brain rupture or leak, leading to bleeding in or around the brain. It is estimated that nearly twenty percent strokes are haemorrhagic strokes. Damage may quickly occur because of pressure exerted by increasing amounts of blood or due to the blood itself. Blood irritates the brain tissue, and makes it swell. Bleeding around the brain is called subarachnoid haemorrhage (SAH), and is generally caused when an anomalous blood vessel (aneurysm) on the brain’s surface ruptures. Bleeding into the brain is known as intracerebral haemorrhage (ICH), and is generally caused by high blood pressure.
Treatment of haemorrhagic stroke depends on the cause of bleeding (e.g. anticoagulant medications, high blood pressure, trauma to the head, blood vessel malformation). Most patients need to be closely monitored in an ICU during and after a haemorrhagic stroke. Care for an individual suffering from haemorrhagic stroke includes identifying the cause of bleeding; regulating blood pressure; and stopping medication that could aggravate bleeding. A ventriculostomy tube is placed in the ventricle to measure pressure in the brain. If the pressure is high, some cerebrospinal fluid may be removed from the ventricle. A ventriculostomy may be employed to drain blood that has accumulated in the brain due to the stroke.
Treatments for haemorrhagic stroke include:
Surgical treatment — Surgery may be carried out to prevent or stop bleeding, or decrease pressure inside the skull. According to severity of stroke and the patient's condition, surgery may be performed within the first forty-eight to seventy-two hours after the haemorrhage; however, it may also be postponed to be done one to two weeks later to let the patient's condition stabilize.
Aneurysm treatment — An aneurysm refers to a blood vessel with a weak spot that protrudes out. If the area ruptures and bleeds, a haemorrhagic stroke could occur.
A clamp could be placed at the aneurysm’s base to prevent bleeding before a stroke or to stop rebleeding. The procedure entails removing a piece of the skull and tracing the aneurysm within the brain tissue; general anesthesia is generally employed and the procedure takes several hours. The piece of skull is replaced after the procedure.
Coil embolization is a procedure less invasive than clipping; it may be performed while the patient is sedated or put to sleep with the help of medicines. A flexible tube (catheter) is inserted into an artery in the groin, guided along blood vessels in the body into the brain vessel with the aneurysm. A minute coil is guided into aneurysm, filling the area with the coil. A blood clot is created within the coil, which blocks blood flow into the aneurysm and prevents it from rupturing again. Other materials may be injected to treat an aneurysm or arteriovenous malformation (AVM). New treatment systems employ stents (flow diverters) that reduce blood flow to the aneurysm.
Arteriovenous malformation treatment — Some AVMs carry a substantial risk of further bleeding. The decision to treat an AVM may depend on many factors, key factors being patient age, AVM location and size, vein abnormalities that drain the malformation, and whether the AVM has bled previously. Treatment could include surgery, radiosurgery, or embolization techniques.
Decompressive craniotomy — This procedure may be decided upon in cases where a patient's life seems threatened by pressure effects of a blood clot in the brain; it entails opening the skull and/or removing the blood. Considerations include size and location of haemorrhage, age and medical condition of patient, and the chances of recovery from the stroke.
Medications for haemorrhagic stroke include:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By type, the market is segmented into:
By distribution channel, the market is divided into:
By region, the market is classified into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2018-2022 |
Forecast Period | 2023-2028 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Type |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Haemorrhagic Stroke Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Haemorrhagic Stroke Treatment Historical Market (2018-2022)
8.3 Global Haemorrhagic Stroke Treatment Market Forecast (2023-2028)
8.4 Global Haemorrhagic Stroke Treatment Market by Drug Type
8.4.1 Antihypertensive
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Anticoagulants
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Anticonvulsants
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Others
8.5 Global Haemorrhagic Stroke Treatment Market by Distribution Channel
8.5.1 Hospitals Pharmacies
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Retail Pharmacies
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Online Pharmacies
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.6 Global Haemorrhagic Stroke Treatment Market by Region
8.6.1 North America
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Europe
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Asia Pacific
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.6.4 Latin America
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2018-2022)
8.6.4.3 Forecast Trend (2023-2028)
8.6.5 Middle East and Africa
8.6.5.1 Market Share
8.6.5.2 Historical Trend (2018-2022)
8.6.5.3 Forecast Trend (2023-2028)
9 North America Haemorrhagic Stroke Treatment Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe Haemorrhagic Stroke Treatment Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Haemorrhagic Stroke Treatment Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Haemorrhagic Stroke Treatment Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Haemorrhagic Stroke Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2022)
13.1.3 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2022)
13.2.3 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2022)
13.3.3 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2022)
13.4.3 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 B. Braun Melsungen AG
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Medtronic
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Bayer AG
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Novartis AG
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Pfizer Inc.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Merck & Co., Inc.
15.2.6.1 Company Overview
15.2.6.2 Product Portfolio
15.2.6.3 Demographic Reach and Achievements
15.2.6.4 Certifications
15.2.7 GlaxoSmithKline plc
15.2.7.1 Company Overview
15.2.7.2 Product Portfolio
15.2.7.3 Demographic Reach and Achievements
15.2.7.4 Certifications
15.2.8 Others
16 Key Trends and Developments in the Market
List of Figures and Tables
1. Global Haemorrhagic Stroke Treatment Market: Key Industry Highlights, 2018 and 2028
2. Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Drug Type (USD Million), 2018-2022
3. Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Drug Type (USD Million), 2023-2028
4. Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Distribution Channel (USD Million), 2018-2022
5. Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Distribution Channel (USD Million), 2023-2028
6. Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Region (USD Million), 2018-2022
7. Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Region (USD Million), 2023-2028
8. North America Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
9. North America Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
10. Europe Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
11. Europe Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Asia Pacific Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
13. Asia Pacific Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Latin America Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
15. Latin America Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Middle East and Africa Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
17. Middle East and Africa Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Global Haemorrhagic Stroke Treatment Market Structure
The global haemorrhagic stroke treatment market is projected to grow at a CAGR of 4.10% between 2023 and 2028.
The major drivers of the market include the high diagnostic rate, availability of the treatment options, high demand of diseases specific treatment, rise in adoption of newer technologies, presence of refined healthcare infrastructure, and increased patient awareness level.
The rising incidences of haemorrhagic stroke and increase healthcare spending are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on drug type, the market is segmented into antihypertensive, anticoagulants, and anticonvulsants, among others.
The several distribution channels of the market are hospitals pharmacies, retail pharmacies, and online pharmacies.
The major players in the industry are B. Braun Melsungen AG, Medtronic, Bayer AG, Novartis AG, Pfizer Inc., Merck & Co., Inc., and GlaxoSmithKline plc, among others.
The global haemorrhagic stroke treatment market was driven by the rising incidences of haemorrhagic stroke in the historical period. Aided by the high diagnostic rate and an increase healthcare spending, the market is expected to witness further growth in the forecast period of 2023-2028, growing at a CAGR of 4.10%.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug type, the market is segmented into antihypertensive, anticoagulants, and anticonvulsants, among others. The several distribution channels of the market are hospitals pharmacies, retail pharmacies, and online pharmacies. The major regional markets for haemorrhagic stroke treatment are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The major players in the industry are B. Braun Melsungen AG, Medtronic, Bayer AG, Novartis AG, Pfizer Inc., Merck & Co., Inc., and GlaxoSmithKline plc, among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.